Teva Pharmaceutical Industries Debt to Equity Ratio 2006-2018 | TEVA

Current and historical debt to equity ratio values for Teva Pharmaceutical Industries (TEVA) over the last 10 years.
Teva Pharmaceutical Industries Annual Debt/Equity Ratio
2017 1.73
2016 1.02
2015 0.33
2014 0.44
2013 0.54
2012 0.64
2011 0.65
2010 0.31
2009 0.29
2008 0.52
2007 0.38
2006 0.48
2005 0.36
Teva Pharmaceutical Industries Quarterly Debt/Equity Ratio
Q2 2018 1.56
Q1 2018 1.53
Q4 2017 1.73
Q3 2017 1.15
Q2 2017 1.18
Q1 2017 0.97
Q4 2016 1.02
Q3 2016 1.00
Q2 2016 0.34
Q1 2016 0.33
Q4 2015 0.33
Q3 2015 0.51
Q2 2015 0.54
Q1 2015 0.49
Q4 2014 0.44
Q3 2014 0.45
Q2 2014 0.47
Q1 2014 0.51
Q4 2013 0.54
Q3 2013 0.56
Q2 2013 0.58
Q1 2013 0.56
Q4 2012 0.64
Q3 2012 0.60
Q2 2012 0.61
Q1 2012 0.63
Q4 2011 0.65
Q3 2011 0.36
Q2 2011 0.27
Q1 2011 0.29
Q4 2010 0.31
Q3 2010 0.33
Q2 2010 0.36
Q1 2010 0.28
Q4 2009 0.29
Q3 2009 0.30
Q2 2009 0.38
Q1 2009 0.52
Q4 2008 0.52
Q3 2008 0.31
Q2 2008 0.32
Q1 2008 0.37
Q4 2007 0.38
Q3 2007 0.41
Q2 2007 0.46
Q1 2007 0.49
Q4 2006 0.48
Q3 2006 0.51
Q2 2006 0.57
Q1 2006 0.61
Q4 2005 0.36
Q3 2005 0.36
Q2 2005 0.40
Q1 2005 0.42
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $22.859B $22.385B
TEVA Pharmaceuticals USA, the business is to develop, manufacture, and market generic pharmaceuticals. Teva USA sells its products to chains, wholesalers, distributors, hospitals, managed care entities, and government agencies. The company markets a variety of dosage forms, including both extended and immediate release tablets and capsules, creams, ointments, solutions, and suspensions. Key therapeutic areas are the analgesic, anti-infective, cardiovascular, CNS, dermatological and anti-inflammatory categories.
Stock Name Country Market Cap PE Ratio
Allergan (AGN) Ireland $62.458B 10.72
Mylan (MYL) United Kingdom $19.184B 8.16
Bausch Health Cos (BHC) Canada $7.619B 5.69
Dr Reddy's Laboratories (RDY) India $5.346B 23.88
Mallinckrodt Public Limited Company (MNK) United Kingdom $2.588B 4.40
Supernus Pharmaceuticals (SUPN) United States $2.410B 25.78
Akorn (AKRX) United States $2.332B 11.55
Assembly Biosciences (ASMB) United States $1.006B 0.00
Amphastar Pharmaceuticals (AMPH) United States $0.801B 115.47
CymaBay Therapeutics (CBAY) United States $0.714B 0.00
Adamas Pharmaceuticals (ADMS) United States $0.628B 0.00
Progenics Pharmaceuticals (PGNX) United States $0.613B 0.00
Voyager Therapeutics (VYGR) United States $0.589B 0.00
Homology Medicines (FIXX) United States $0.582B 0.00
Corium (CORI) United States $0.314B 0.00
Teligent (TLGT) United States $0.220B 0.00
Sol-Gel Technologies (SLGL) Israel $0.124B 0.00
Zynerba Pharmaceuticals (ZYNE) United States $0.115B 0.00
Aquinox Pharmaceuticals (AQXP) Canada $0.073B 0.00
Versartis (VSAR) United States $0.063B 0.00
Aevi Genomic Medicine (GNMX) United States $0.058B 0.00
Evoke Pharma (EVOK) United States $0.043B 0.00
Pernix Therapeutics Holdings (PTX) United States $0.023B 0.00
Acasti Pharma (ACST) Canada $0.019B 0.00
China Pharma Holdings (CPHI) China $0.010B 0.00
Agile Therapeutics (AGRX) United States $0.009B 0.00